AN UNBIASED VIEW OF ELAFIBRANOR

Ibrutinib, as one agent, is efficient in dealing with CLL, distinctive subtypes of lymphoma together with other B-cell malignancies Until unacceptable toxicity or disease progression is noticed. As a result of chronic exposure of ibrutinib during remedy, lymphoma cells could attain compensatory survival pathways, genetic mutations or clonal variety